

AMENDMENTS TO THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. (Currently amended) A method for ~~modulating~~preventing, inhibiting or otherwise down-regulating immuno-activity of an antigen presenting cell (APC), said method comprising contacting said cell with an effective amount of an ~~agent~~antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with a ~~cell surface activation molecule and in turn~~CMRF-44 thereby ~~prevents~~preventing, inhibits~~inhibiting~~ or otherwise ~~down-regulates~~down-regulating one or more functional activities of said cell the immuno-activity of said cell.
2. (Original) The method of claim 1 wherein the APC is selected from a dendritic cell (DC), follicular DC, macrophage and B cell.
3. (Original) The method of claim 2 wherein the APC is a DC.
4. (Original) The method of claim 3 wherein the DC is a myeloid DC.
5. (Original) The method of claim 4 wherein the DC is a CD11c⁺ DC.
- 6-7. (Canceled)
8. (Currently amended) The method of claim ~~[[7]]~~1 wherein the antibody is a monoclonal antibody or a ~~functional equivalent thereof~~.
9. (Canceled)
10. (Currently amended) The method of claim ~~[[9]]~~1 wherein the CMRF-44 antibody or its ~~functional equivalent~~antigen-binding fragment thereof is capable of inducing lysis of the APC.
11. (Original) The method of claim 1 wherein the cell is mammalian derived.

12. (Original) The method of claim 11 wherein the mammalian cell is a human cell.
13. (Canceled)
14. (Original) The method of claim 10 wherein lysis is caused by antibody-dependent cell-mediated cytotoxicity.
15. (Currently amended) The method of claim ~~7 or 8 or 9 or 10~~ 1 wherein the antibody or antigen-binding fragment thereof in conjugated with a toxic component which kills or otherwise facilitates lysis of the APC.
16. (Currently amended) A method for ~~modulating~~preventing, inhibiting or otherwise down-regulating the immuno-activity of APC ~~and/or lymphocyte~~, said method comprising contacting said APC with an effective amount of a monoclonal antibody to a cell-surface antigenCMRF-44 or antigen-binding fragment thereof for a time and under conditions sufficient to induce lysis or cell death of said ~~cell~~APC.
17. (Canceled)
18. (Currently amended) The method of claim 16 ~~or 17~~ wherein the APC is DC.
19. (Original) The method of claim 18 wherein the DC is a CD11⁺DC.
20. (Currently amended) A method for ~~modulating~~preventing, inhibiting or otherwise down-regulating an immune response in a subject, said method comprising administering to said subject an effective amount of an ~~agent~~antibody or antigen-binding fragment thereof, which ~~agent~~ agent couples, binds or otherwise associates with an APC surface activation moleculeCMRF-44 for a time and under conditions sufficient to ~~prevent, inhibit or otherwise down-regulate one or more functional activities thereby preventing, inhibiting or otherwise down-regulating the immune response~~ prevent, inhibit or otherwise down-regulate one or more functional activities thereby preventing, inhibiting or otherwise down-regulating the immune response of said APC.

21. (Original) The method of claim 20 wherein the APC is DC.
22. (Original) The method of claim 21 wherein the DC is a CD11⁺DC.
- 23-24. (Canceled)
25. (Currently amended) A method for down-regulating the immuno-activity of an immune-competent graft in a subject, said method comprising administering to said subject an effective amount of an antibody specific for CMRF-44 ~~or its functional equivalent on an APC~~ or an antigen-binding fragment thereof, for a time and under conditions sufficient to induce lysis or death of said APC.
26. (Currently amended) A method for down-regulating the immuno-activity of a bone marrow graft in a subject, said method comprising administering to said subject an effective amount of an antibody specific for CMRF-44 ~~or its functional equivalent on an APC~~ or an antigen-binding fragment thereof, for a time and under conditions sufficient to induce lysis or death of said APC.
27. (Currently amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising contacting said graft in said subject with an effective amount of an antibody specific for CMRF-44 ~~or its functional equivalent on an APC~~ or an antigen-binding fragment thereof, for a time and under conditions sufficient to induce lysis or death of said APC.
28. (Original) The method of claim 25 or 26 or 27 wherein the APC is DC.
29. (Original) The method of claim 28 wherein the DC is a CD11⁺DC.
30. (Original) The method of claim 25 or 26 or 27 wherein the antibody is a monoclonal antibody.

31-32. (Canceled)

33. (New) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising prior to implantation of said graft in said subject, contacting said graft with an effective amount of an antibody specific for CMRF-44 or an antigen-binding fragment thereof *in vitro* for a time and under conditions sufficient to induce lysis or death of said APC.